A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

Last updated:
2026-09-12
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL OF ARV-471 (PF-07850327) VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE (VERITAC-2)

Intervention/treatment:
VEPDEGESTRANT (ARV-471, PF-07850327)/ FULVESTRANT
Medical condition:
BREAST CANCER
Protocol code:
C4891001
Control number:
269190
Status:
Active, not recruiting
Approved:
December 19, 2022
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT05654623
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Pfizer ClinicalTrials.gov Call Center
Organization
Pfizer Inc.
Phone:
1-800-718-1021
Sponsor
PFIZER CANADA ULC

Locations

Alberta

Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2

British Columbia

BC Cancer Surrey
Surrey, British Columbia, V3V 1Z2

New Brunswick

The Moncton Hospital
Moncton, New Brunswick, E1C 6Z8

Ontario

Sunnybrook Research Institute
Toronto, Ontario, M4N 3M5
Unity Health Toronto, St. Michael's Hospital
Toronto, Ontario, M5B 1W8
Waterloo Regional Health Network
Kitchener, Ontario, N2G 1G3

Quebec

Centre de Services Ambulatoires de St-Jerome
Saint-Jérôme, Quebec, J7Y 0L1
Unité de Recherche Clinique du CISSS des Laurentides
Saint-Jérôme, Quebec, J7Z 2V4

Results

See the results from the trial NCT05654623. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?